Striatal atrophy and mHtt aggregation.

<p>(A) Striatal mHtt aggregation was mitigated in ASCs-E treated group. (B) mHtt aggregation was visualized by western blot. (C) mHtt aggregation level was higher in ASCs-E treated R6/2 mouse brain compared with R6/2 control. (D) Striatum was sectioned and stained with Nissl in R6/2 mouse treated with ASCs-E or vehicle. (E) Striatum/peristriatum ratio is higher in ASCs-E injected group compared with vehicle treated group. Bar  = 100 μm, * <i>p</i><0.01.</p

Experimental schedule and disease phenotypes of R6/2 mice.

<p>(A) Schedule for ASCs-E injection, behavior test, weight measure and brain sampling. (B) ASCs-E injection mitigated weight loss in R6/2 mouse at 12 weeks age. (C) Rotarod test showed better motor performance at 10, 11 and 12 weeks of age in ASCs-E treated R6/2 compared with control. * <i>p</i><0.05, ** <i>p</i><0.01.</p

Restoration of p-Akt, CREB and PGC-1α by ASCs-E.

<p>(A) Western blot analysis confirmed that upregulation of PGC-1α, p-CREB and p-Akt in ASCs-E treated R6/2 mice brain and (B) PGC-1α and p-CREB in ASCs-E treated neuro2A cells. Bar graphs show the relative levels of protein expressions normalized to β-actin. * <i>p</i><0.05.</p

Univariable analysis using the GEE model.

<p>GEE indicates generalized estimating equations; RR, rate ratio; CI, confidence interval; NIHSS, National Institute of Health Stroke Scale; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker.</p

Estimated annual rates of change of MB counts.

<p>MB indicates microbleed.</p

Multivariable analysis using the GEE model.

<p>Multivariable analysis using the GEE model.</p

Baseline characteristics of patients according to presence of MBs at baseline.

<p>MB indicates microbleed; TIA, transient ischemic attack; NIHSS, National Institute of Health Stroke Scale; LDL, low-density lipoprotein; HDL, high-density lipoprotein; NS, not significant.</p><p>Student <i>t</i>-tests or χ² tests were used.</p><p>*indicates <i>p</i><0.05.</p

Dynamic changes of MBs over a long-term MRI follow-up.

<p>Some new MBs appeared (A), and some MBs disappeared in the follow-up MRI (B). Black arrows represent the MRI follow-up, while white arrow heads indicate new MBs, and dotted circles identify the location of those MBs which had disappeared.</p

Baseline clinical and laboratory characteristics of the patients.

<p>Baseline clinical and laboratory characteristics of the patients.</p

Measured NGF levels (mean level with standard deviation in parentheses) according to the subgroups.

<p>Measured NGF levels (mean level with standard deviation in parentheses) according to the subgroups.</p